EFEITOS ADVERSOS EM PUÉRPERAS HIPERTENSAS TRATADAS COM CAPTOPRIL VERSUS METILDOPA

Abstract

Hypertensive syndromes during pregnancy are the main causes of maternal mortality in Brazil, being present in almost 10% of pregnancies. The control of these diseases also in the postpartum period is important to prevent complications such as eclampsia and HELLP syndrome, reducing maternal and neonatal morbidity and mortality. The present study is derived from the randomized clinical trial "A randomized controlled trial on management of hypertension on early puerperium: methyldopa maintenance versus angiotensin converting enzyme inhibitor substitution" and aimed to evaluate the adverse effects of puerperal women with one of these syndromes treated with methyldopa or captopril in the postpartum period. The results showed that there was no statistical significance between the symptoms reported by the two groups of patients, and the satisfaction of the women regarding the drug used was also similar. Thus, we perceived that both medications are safe and comfortable for pressure control in the immediate puerperium.